[Clinical immunopharmacology of RU 41740].
The clinical immunopharmacology of RU 41740 was studied in man by means of double-blind, drug versus placebo trials. When the compound was administered concomitantly with an anti-influenza vaccine, the anti-influenza antibody titers were higher than in the group which received a placebo. RU 41740 increased delayed hypersensitivity as demonstrated in vitro by lymphocyte proliferation tests in treated subjects and in vivo by cutaneous reactions in patients with malignant diseases. The drug was also found to stimulate phogocytosis in patients with chronic bronchitis. These studies show that RU 41740 has a non-specific enhancing effect on humoral and cellular immune responses and on phagocytic functions.
Boissier
M C
MC
Unité de Recherches sur la Pathologie autoimmune, (INSERM U283), Hôpital Cochin, Paris.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D001426:Bacterial Proteins / Q000494:pharmacology*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007251:Influenza, Human / Q000276:immunology*; D008297:Male; D010587:Phagocytosis / Q000187:drug effects; D014611:Vaccination
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; C037567:glycoprotein, Klebsiella pneumoniae
Immunopharmacologie clinique du RU 41740.